CoChat

Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer’s disease: A longitudinal retrospective study

Open access

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Background Post-mortem studies have not identified an association between β-amyloid or tau and rates of hippocampal atrophy in patients with Alzheimer's disease. TAR DNA binding protein 43 (TDP-43) is another protein linked to Alzheimer's disease. We aimed to investigate whether hippocampal TDP-43 is associated with increased rates of hippocampal atrophy.Methods In this longitudinal retrospective study, we analysed post-mortem brain tissue of all individuals with an Alzheimer's disease spectrum pathological diagnosis who had antemortem head MRI scans between Jan 1, 1999, and Dec 31, 2012, and who had been recruited into the Mayo Clinic Alzheimer's Disease Research Center, Mayo Clinic Alzheimer's Disease Patient Registry, or the Mayo Clinic Study of Aging. We did TDP-43 immunohistochemistry and classified individuals as follows: no TDP-43 in the amygdala or hippocampus; TDP-43 restricted to the amygdala; and TDP-43 spreading into the hippocampus. Each individual was also assigned a neurofibrillary tangle stage (B1-B3), relating to the likelihood of having Alzheimer's disease. We used longitudinal FreeSurfer software and tensor-based morphometry with symmetric normalisation to calculate hippocampal volume on all serial MRI scans and used linear mixed-effects regression models to estimate associations between TDP-43 and rate of hippocampal atrophy and to assess the trajectory of TDP-43-associated atrophy.Findings We identified 298 individuals meeting the inclusion criteria, with 816 usable MRI scans (spanning 1·0-11·2 years of the disease) available for analysis. 141 individuals showed no TDP-43 in the amygdala or hippocampus, 33 had TDP-43 restricted to the amygdala, and 124 had TDP-43 in the hippocampus. Among individuals with a high likelihood of having Alzheimer's disease (neurofibrillary tangle stage B3; n=205), those with hippocampal TDP-43 had faster rates of hippocampal atrophy (n=103, annual volume change -4·39%, 95% CI -4·82 to -3·95; p<0·0001) than did those with amygdala-only TDP-43 (n=20, -3·29%, -4·11 to -2·46; p<0·0001; difference -1·10%, 95% CI -2·02 to -0·19; p=0·02) and those without TDP-43 (n=82, -3·11%, -3·54 to -2·68; p<0·0001; difference -1·28%, -1·88 to -0·67; p<0·0001). Among individuals with an intermediate likelihood of having Alzheimer's disease (neurofibrillary tangle stage B2; n=56), those with hippocampal TDP-43 had faster rates of hippocampal atrophy (n=17, annual volume change -4·05%, 95% CI -5·09 to -2·99; p<0·0001) than did those with amygdala-only TDP-43 (n=6, -1·78%, -3·04 to -0·55; p=0·004; difference -2·27%, 95% CI -3·79 to -0·67; p=0·006) and those without TDP-43 (n=33, -1·63%, -2·43 to -0·83; p=0·0002; difference -2·43%, -3·66 to -1·18; p=0·0002). Hippocampal TDP-43 was not associated with the rate of hippocampal atrophy in individuals with a low likelihood of having Alzheimer's disease (neurofibrillary tangle stage B1; n=37). The trajectory analysis suggested that increased rates of TDP-43-associated hippocampal atrophy might occur at least 10 years before death. Results were similar for FreeSurfer and tensor-based morphometry.Interpretation TDP-43 should be considered as a potential factor related to increased rates of hippocampal atrophy in patients with Alzheimer's disease. Given the importance of hippocampal atrophy in Alzheimer's disease, it is imperative that techniques are developed for detection of TDP-43 in vivo.Funding US National Institute on Aging (National Institutes of Health).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(17)30284-3

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Analyses of FreeSurfer hippocampal atrophy rates by TDP-43 and neurofibrillary tangle stages based on linear mixed effects regression modeling. (A) Shows hippocampal atrophy rates, expressed as an annual percent volume change, by TDP-43 stage separately for neurofibrillary tangles stages B1, B2, and B3. (B) Compares the rates of hippocampal atrophy, expressed as differences in annual percent volume change, between TDP-43 stages for each of the three neurofibrillary tangle stages. Annual percent volume changes and group-wise difference values are provided in Appendix, p8.
Figure 1 Analyses of FreeSurfer hippocampal atrophy rates by TDP-43 and neurofibrillary tangle stages based on linear mixed effects regression modeling. (A) Shows hippocampal atrophy rates, expressed as an annual percent volume change, by TDP-43 stage separately for neurofibrillary tangles stages B1, B2, and B3. (B) Compares the rates of hippocampal atrophy, expressed as differences in annual percent volume change, between TDP-43 stages for each of the three neurofibrillary tangle stages. Annual percent volume changes and group-wise difference values are provided in Appendix, p8.CC BY-NC-ND · PubMed Central
Figure 2 Analyses of FreeSurfer hippocampal atrophy rates by TDP-43 and amyloid stage (amyloid- (A0), and amyloid + (A1)) based on linear mixed effects regression modeling. (A) Shows hippocampal atrophy rates, expressed as an annual percent volume change, by TDP-43 stage separately for two amyloid stages. (B) Compares the rates of hippocampal atrophy, expressed as differences in annual percent volume change, between TDP-43 stages for each of the two amyloid stages. Annual percent volume changes and group-wise difference values are provided in Appendix, p8.
Figure 2 Analyses of FreeSurfer hippocampal atrophy rates by TDP-43 and amyloid stage (amyloid- (A0), and amyloid + (A1)) based on linear mixed effects regression modeling. (A) Shows hippocampal atrophy rates, expressed as an annual percent volume change, by TDP-43 stage separately for two amyloid stages. (B) Compares the rates of hippocampal atrophy, expressed as differences in annual percent volume change, between TDP-43 stages for each of the two amyloid stages. Annual percent volume changes and group-wise difference values are provided in Appendix, p8.CC BY-NC-ND · PubMed Central
Figure 3 Trajectories of FreeSurfer hippocampal volumes for cases with and without hippocampal TDP-43 based on linear mixed effects regression modeling. The estimates assumed age at death of 80 years, MRI scan field strength of 1.5T, and a total intracranial volume of 1.4L. Note that cases with TDP-43 in the hippocampus (TDP+) had faster rates of hippocampal atrophy compared to cases without TDP-43 in the hippocampus (TDP−). The separation of the confidence intervals of the trajectories appears roughly a decade prior to death. Tick marks on the x-axis indicate available MRI data points in terms of years from death. Overall, on an annual basis and assuming death at age 80 years, mean decline was an estimated 0.19 cm3/year (95% CI, 0.17 to 0.20).
Figure 3 Trajectories of FreeSurfer hippocampal volumes for cases with and without hippocampal TDP-43 based on linear mixed effects regression modeling. The estimates assumed age at death of 80 years, MRI scan field strength of 1.5T, and a total intracranial volume of 1.4L. Note that cases with TDP-43 in the hippocampus (TDP+) had faster rates of hippocampal atrophy compared to cases without TDP-43 in the hippocampus (TDP−). The separation of the confidence intervals of the trajectories appears roughly a decade prior to death. Tick marks on the x-axis indicate available MRI data points in terms of years from death. Overall, on an annual basis and assuming death at age 80 years, mean decline was an estimated 0.19 cm3/year (95% CI, 0.17 to 0.20).CC BY-NC-ND · PubMed Central
Figure 4 Models assessing the role of additional pathologies. (A) Analysis of the independent effect of each of multiple pathologies on hippocampal atrophy rates based on linear mixed effects regression modeling assuming no interactions among the effects. Estimates are from a mixed model with TDP-43, neurofibrillary tangle (NFT) stage, amyloid positivity, hippocampal sclerosis, and age at death. For reference, the estimated rate of decline for an individual who died at age 80 with TDP Stage 0, NFT Stage B1, no amyloid, and no hippocampal sclerosis is 0.7% per year (95% CI, −1.7 to +0.25). (B) FreeSurfer hippocampal atrophy rates in each TDP-43 stage contrasting those with neurofibrillary tangle stage B3 versus those with neurofibrillary tangle stage of B1 or B2. The atrophy rates are statistically significant in TDP-43 stages 0 and 1. Group-wise difference values are provided in Appendix, p8.
Figure 4 Models assessing the role of additional pathologies. (A) Analysis of the independent effect of each of multiple pathologies on hippocampal atrophy rates based on linear mixed effects regression modeling assuming no interactions among the effects. Estimates are from a mixed model with TDP-43, neurofibrillary tangle (NFT) stage, amyloid positivity, hippocampal sclerosis, and age at death. For reference, the estimated rate of decline for an individual who died at age 80 with TDP Stage 0, NFT Stage B1, no amyloid, and no hippocampal sclerosis is 0.7% per year (95% CI, −1.7 to +0.25). (B) FreeSurfer hippocampal atrophy rates in each TDP-43 stage contrasting those with neurofibrillary tangle stage B3 versus those with neurofibrillary tangle stage of B1 or B2. The atrophy rates are statistically significant in TDP-43 stages 0 and 1. Group-wise difference values are provided in Appendix, p8.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 283

Metadata

Authors
Josephs, K. A., Dickson, D. W., Tosakulwong, N., Weigand, S. D., Murray, M. E., Petrucelli, L., Liesinger, A. M., Senjem, M. L., Spychalla, A. J., Knopman, D. S., Parisi, J. E., Petersen, R. C., Jack, C. R., & Whitwell, J. L.
Affiliations
  • Mayo Clinic (US)
  • Mayo Clinic in Florida (US)
Corresponding author
Josephs, Keith A
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2017-11
Volume
16
Issue
11
Pages
917-924
ISSN
1474-4422 (ISSN-L)
OpenAlex
W2755222361
Cited by
252
References
33
Citations by year
2026: 28 · 2025: 34 · 2024: 37 · 2023: 30 · 2022: 24 · 2021: 23 · 2020: 35 · 2019: 27 · 2018: 13 · 2017: 1
FWCI
17.06
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc-nd
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (acceptedVersion, cc-by-nc-nd)
Funders
  • National Institutes of Health
  • National Institute on Aging (R01 AG041851, R01 AG037491, U01 AG006786, R01 AG11378, P50 AG16574)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
Keywords
Alzheimer's disease, TDP-43, hippocampal atrophy, amygdala, neurofibrillary tangles, hippocampal volume, atrophy rate, postmortem neuropathology, longitudinal MRI, Mayo Clinic Study of Aging, neurodegeneration biomarkers, amyloid-beta
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Amygdala, Apolipoproteins E, Atrophy, Diagnosis, DNA-Binding Proteins, Female, Hippocampus, Humans, Longitudinal Studies, Magnetic Resonance Imaging, Male, Psychiatric Status Rating Scales, Retrospective Studies, tau Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer’s disease: A longitudinal retrospective study. https://app.cochat.ai/papers/10.1016/s1474-4422(17)30284-3
The paper
Josephs, K. A., Dickson, D. W., Tosakulwong, N., Weigand, S. D., Murray, M. E., Petrucelli, L., Liesinger, A. M., Senjem, M. L., Spychalla, A. J., Knopman, D. S., Parisi, J. E., Petersen, R. C., Jack, C. R., & Whitwell, J. L. (2017). Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer’s disease: A longitudinal retrospective study. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(17)30284-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.